Simulations Plus: Solid Q2 and Long-Term Potential Tempered by EPS Headwinds and Biopharma Spending Uncertainty Supporting Hold Rating

Brendan Smith, an analyst from TD Cowen, maintained the Hold rating on Simulations Plus. The associated price target is $16.00.

Brendan Smith has given his Hold rating due to a combination of factors, including steady but not breakout growth and a reduced price target. Simulations Plus delivered solid fiscal Q2 results with mid‑single‑digit to high‑single‑digit revenue growth, led by core development software and services, but this strength was partly offset by weakness in commercial and clinical operations.

Management reaffirmed its longer‑term revenue and adjusted EBITDA outlook, yet lowered EPS expectations because of a higher projected tax rate, which tempers the earnings trajectory. New key performance indicators and cross‑selling opportunities suggest upside potential over time, but ongoing macro and biopharma spending uncertainties, along with timing risks around a fuller recovery across segments, justify a more balanced, wait‑and‑see stance rather than a more aggressive rating.

According to TipRanks, Smith is an analyst with an average return of -1.9% and a 34.55% success rate. Smith covers the Healthcare sector, focusing on stocks such as Halozyme, West Pharmaceutical Services, and Azenta.